Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 71.7% in November

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the recipient of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 49,500 shares, a decline of 71.7% from the November 15th total of 175,000 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 172,900 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Ratings Changes

ADIL has been the topic of several analyst reports. Rodman & Renshaw initiated coverage on Adial Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $8.00 price target on the stock. RODMAN&RENSHAW raised shares of Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th.

Adial Pharmaceuticals Trading Down 0.9 %

Adial Pharmaceuticals stock opened at $1.09 on Friday. Adial Pharmaceuticals has a 52 week low of $0.77 and a 52 week high of $4.17. The business’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $1.08.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.